Phibro Animal Health (NASDAQ:PAHC) Releases FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.340-1.480 for the period, compared to the consensus earnings per share estimate of 1.550. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Phibro Animal Health Stock Up 1.1 %

Shares of Phibro Animal Health stock traded up $0.24 during trading hours on Wednesday, reaching $23.09. 203,441 shares of the company were exchanged, compared to its average volume of 154,705. Phibro Animal Health has a 1 year low of $9.40 and a 1 year high of $25.11. The stock’s fifty day moving average is $22.28 and its 200 day moving average is $19.24. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.64 and a current ratio of 2.94. The firm has a market cap of $935.15 million, a PE ratio of 384.90, a PEG ratio of 0.55 and a beta of 0.51.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.34 by $0.07. The firm had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. Phibro Animal Health had a return on equity of 18.08% and a net margin of 0.24%. As a group, equities research analysts forecast that Phibro Animal Health will post 1.57 earnings per share for the current year.

Analyst Ratings Changes

PAHC has been the subject of several research analyst reports. Bank of America upped their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective for the company. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.00.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the purchase, the director now owns 25,000 shares of the company’s stock, valued at approximately $500,500. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 50.07% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.